S
SignalPath
SignalPath is designing the next generation of software for the clinical research site
About SignalPath
SignalPath operates as a clinical trial technology company, providing a sophisticated management platform to enhance the efficiency and execution of clinical research. The firm was established in 2014 by Dr. Brad Hirsch and Kevin Monroe. Dr. Hirsch, a medical oncologist, drew from his experiences as a faculty member at Duke University and roles at Flatiron Health and US Oncology to address the significant limitations in clinical trial execution. His insight was that existing processes were inefficient for patients, research sites, and trial sponsors, creating a need for better technology to manage trial ease, efficiency, and profitability.
Read full description
The company's core offering is a cloud-based, HIPAA-compliant Clinical Trial Management System (CTMS), now known as Verily Viewpoint Site CTMS following its acquisition. This platform serves clinical research sites, healthcare organizations, and pharmaceutical companies by digitizing study protocols, which transforms static documents into dynamic, digital models. This digitization is a key feature, powering all clinical and financial workflows, reducing manual tasks, and unifying siloed processes. The system includes tools for study, site, and participant management, financial and budget management, document management, data capture, and regulatory compliance. It aims to reduce fragmentation by optimizing the management of a site's entire clinical trials portfolio.
SignalPath's business model is centered on a subscription-based service for its CTMS platform, complemented by bundled services like data analytics and integration support. A significant milestone in the company's history was its acquisition by Verily, an Alphabet company, which was announced in August 2021. This strategic move integrated SignalPath's technology into Verily's Baseline platform, expanding its capabilities in evidence generation, decentralized trials, and real-world data collection. The acquisition allowed SignalPath to scale its solutions and provide its network of research sites with a broader range of resources and trial opportunities.
At a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Raleigh, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 70.0/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, Clinical, Medical Data, Hard Tech, Health It
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning SignalPath.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2021 | $0 | — | Verily | — |
| SERIES B✓Equity / VC | Oct 2019 | $18M | $72M | Undisclosed | — |
Growth signals
Latest recorded traffic for SignalPath is 3.1K monthly website visits, up 138.5% over the last three months. SignalPath's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Verily
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SignalPath on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SignalPath’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.